SCH 66336

What SCH 66336 Means in Everyday Medical Language

Lonafarnib, also known as SCH 66336, is a medicine taken by mouth that blocks an enzyme called farnesyltransferase. This enzyme adds a small chemical group to certain proteins, which is important for their normal function. Some of these proteins, like Ras, play roles in how cells grow and age. By blocking this enzyme, lonafarnib changes how these proteins work in the body.

Lonafarnib is sold under the brand name Zokinvy and is mainly used to treat Hutchinson-Gilford progeria syndrome (HGPS). This is a very rare genetic disorder where children show signs of aging very early in life. It is also used for related conditions called progeroid laminopathies, which have similar genetic causes and symptoms.

Why Lonafarnib Can Matter in Cancer Care and Other Diseases

Lonafarnib was originally developed to treat cancers driven by abnormal Ras proteins, which are involved in about 30% of human cancers such as pancreatic, colorectal, and lung cancers. It was tested in many clinical trials but did not become a standard cancer treatment because it was not effective enough on its own.

However, lonafarnib’s ability to block farnesyltransferase has proven useful in treating progeria, where it helps reduce harmful buildup of defective proteins that cause early aging symptoms. It has also shown promise in treating hepatitis D virus infections when combined with other medicines like ritonavir.

What Patients Might See or Hear About Lonafarnib

If lonafarnib is mentioned in your medical records, treatment plan, or discussions, it may be called by its other name, SCH 66336. You might hear about it as a treatment for progeria or in clinical trials for hepatitis D or cancer. Common side effects include nausea, vomiting, headache, diarrhea, decreased appetite, and fatigue.

Because lonafarnib affects important proteins in cells, doctors carefully monitor patients for side effects and drug interactions. For example, it should not be taken with certain medicines that affect liver enzymes, as this can change how lonafarnib works in the body.

Where You Might Encounter the Term Lonafarnib

Lonafarnib may appear in your medical records, especially if you or a loved one is being treated for progeria or related conditions. It can also be mentioned in clinical trial information, drug fact sheets, or cancer-related resources. Sometimes it appears alongside other drugs like ritonavir, especially in studies of hepatitis D virus treatment.

What Lonafarnib Does Not Automatically Mean

Seeing lonafarnib mentioned does not mean you have cancer or progeria. It is a medication that may be part of a treatment plan or a research study. It also does not guarantee a cure or full control of a disease. Its use and effects depend on the specific condition and individual patient factors.

Common Questions to Ask Your Care Team

If lonafarnib comes up in your care, you might ask: What is lonafarnib being used for in my or my loved one’s treatment? What benefits and risks should I expect? Are there side effects I should watch for? How will this medicine interact with other treatments I am receiving? What monitoring will be done while taking lonafarnib?

Understanding This Information and Next Steps

This information is meant to help you understand what lonafarnib (SCH 66336) is and why it might be mentioned in your care. It does not replace advice from your healthcare team. If you see this term in your medical records or hear it during visits, the best next step is to ask your doctor or nurse what it means for your specific situation. They can explain how it fits into your treatment plan and what to expect.